Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Market Gems-Trading Strong Earnings Growth and Momentum -- Ignore unavailable to you. Want to Upgrade?

To: 2MAR$ who wrote (1846)	1/16/2001 2:40:51 PM
From: 2MAR$	Respond to of 6445

Biogen says trial of MS drug Avorex was successful NEW YORK, Jan 16 (Reuters) - Biotechnology company Biogen Inc. <BGEN.O> said on Tuesday that a trial of Avorex was successful after the drug reduced the progression of disability of secondary progressive multiple sclerosis by 27 percent compared with patients treated with placebo. The study on Avorex began in 1998 and involved 436 patients at 42 sites in the United States, Canada, and Europe, the Cambridge, Mass.-based company said in a release. Biogen shares were up $3 at $54-13/16, up from a year low of $47-2/16 and below a 52-week high of $129. ((New York newsdesk 212 859 1700))